Companies like Pathway Genomics and Klotho Therapeutics are dedicated to helping people prevent or delay the onset of diseases associated with aging. Pathway Genomics focuses on genetic testing, while Klotho Therapeutics is a biotechnology company concentrating on a specific natural human protein that has numerous positive effects for staying healthy longer. Both companies were founded by James Plante.
Delaying Age-Related Illness
A major goal for Klotho Therapeutics is for people to age more gracefully without the suffering caused by dementia, kidney disease and cancer. All these illnesses are relatively common by retirement age. So far, the diseases may not be fully preventable, but the delay process shows great promise. And the longer illnesses can be delayed, the more likely it is that researchers will discover more effective treatments and even cures.
The Battle Against Kidney Disease
The substance being developed by this particular organization is a form of the human Klotho protein created through biotechnology. The main focus for the organization currently is to use this biotechnology to tackle kidney disease, which is relatively common in the U.S. population. About 14 percent of U.S. residents are afflicted with chronic kidney disease. The organs no longer filter waste materials from the blood as effectively as they are supposed to.
Frequently, another illness eventually leads to kidney damage. Diabetes and cardiovascular disease are the most significant examples, as they are hard on those organs. Since adequate amounts of the Klotho protein can help prevent or delay the onset of those problems, overall better health should be the result.
In addition to the human distress and suffering caused by kidney disorders, treatment of chronic kidney disease costs billions of dollars annually in the United States alone. Much of that money comes through Medicare, since people age 65 and over are more susceptible to this illness.
People with late-stage kidney disease or kidney failure manage the disorder through regular dialysis treatments. Some are on a transplant waiting list. Nearly 18,000 kidney transplants are performed each year. Patients often must wait at least three years before they reach the top of the wait list.